Blood Pyrrole-Protein Adducts-A Biomarker of Pyrrolizidine Alkaloid-Induced Liver Injury in Humans

Journal of Environmental Science and Health - Part C Environmental Carcinogenesis and Ecotoxicology Reviews

Volumn 33, Issue 4, 2015, Pages 404-421

  Ruan, Jianqing ^a   Gao, Hong ^b   Li, Na ^a   Xue, Junyi ^a,c   Chen, Jie ^b   Ke, Changqiang ^c,d   Ye, Yang ^c,d   Fu, Peter Pi Cheng ^e   Zheng, Jiang ^f,g   Wang, Jiyao ^b   Lin, Ge ^a,c  

^a Prince of Wales Hospital   (Hong Kong)

^b FUDAN UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^e NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

hepatic sinusoidal obstruction syndrome; hepatotoxicity; pyrrole protein adducts; pyrrolizidine alkaloids

Indexed keywords

ALKALOIDS; AROMATIC COMPOUNDS; BIOMARKERS; BLOOD; CHEMICAL COMPOUNDS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INSPECTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITES;

HEPATIC SINUSOIDAL OBSTRUCTION SYNDROME; HEPATOTOXICITY; LIVER INJURIES; PROTEIN ADDUCTS; PYRROLIZIDINE ALKALOID; TRIPLE-QUADRUPOLE MASS SPECTROMETRY; U-HPLC-MS; ULTRA-HIGH PERFORMANCE LIQUID CHROMATOGRAPHIES;

PROTEINS;

7,9 DIGLUTATHIONE 6,7 DIHYDRO 7 HYDROXY 1 HYDROXYMETHYL 5H PYRROLIZINE; BIOLOGICAL MARKER; GYNURA SEGETUM ALKALOID EXTRACT; PLANT EXTRACT; PROTEIN; PYRROLE; PYRROLIZIDINE ALKALOID; PYRROLIZINE DERIVATIVE; SENECIONINE; SENECIPHYLLINE; UNCLASSIFIED DRUG; PYRROLE DERIVATIVE; TOXIN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; FEMALE; GYNURA SEGETUM; HERB; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIVER TOXICITY; MALE; MEDICINAL PLANT; MIDDLE AGED; NONHUMAN; PROTEIN BLOOD LEVEL; QUADRUPOLE MASS SPECTROMETRY; RAT; RISK ASSESSMENT; TOXIC HEPATITIS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ADOLESCENT; ANIMAL; BLOOD; CHEMISTRY; DRUG-INDUCED LIVER INJURY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER VEIN OBSTRUCTION; METABOLISM; TOXICITY TESTING;

ADOLESCENT; ADULT; AGED; ANIMALS; BIOMARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG-INDUCED LIVER INJURY; FEMALE; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; MALE; MIDDLE AGED; PYRROLES; PYRROLIZIDINE ALKALOIDS; RATS; TOXICITY TESTS; TOXINS, BIOLOGICAL;

EID: 84948767173     PISSN: 10590501     EISSN: 15324095     Source Type: Journal    
DOI: 10.1080/10590501.2015.1096882     Document Type: Article

References (50)

1. Sgro C., Clinard F., Ouazir K. et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002; 36: 451-5.
2. Ibanez L., Perez E., Vidal X. et al. Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol. 2002; 37: 592-600.
3. Grant LM., Rockey DC. Drug-induced liver injury. Curr Opin Gastroenterol. 2012; 28: 198-202.
4. Ostapowicz G., Fontana RJ., Schiodt FV. et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002; 137: 947-54.
5. Chen S., Melchior WB Jr., Guo L. Endoplasmic reticulum stress in drug-And environmental toxicant-induced liver toxicity. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2014; 32: 83-104.
6. Suk KT., Kim DJ. Drug-induced liver injury: present and future. Clin Mol Hepatol. 2012; 18: 249-57.
7. Zhao P., Wang C., Liu W. et al. Acute liver failure associated with traditional Chinese medicine: report of 30 cases from seven tertiary hospitals in China. Crit Care Med. 2014; 42: e296-9.
8. Stickel F., Patsenker E., Schuppan D. Herbal hepatotoxicity. J Hepatol. 2005; 43: 901-910.
9. Wai CT., Tan BH., Chan CL. et al. Drug-induced liver injury at an Asian center: a prospective study. Liver Int. 2007; 27: 465-74.
10. Hu YY., Huang F. Chinese herb and drug-induced liver injury. Chinese Journal of Hepatology. 2012; 20: 173-5.
11. Bunchorntavakul C., Reddy KR. Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther. 2013; 37: 3-17.
12. Larrey D., Faure S. Herbal medicine hepatotoxicity: a new step with development of specific biomarkers. J Hepatol. 2011; 54: 599-01.
13. Navarro VJ., Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006; 354: 731-39.
14. Chojkier M. Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids. J Hepatol. 2003; 39: 437-46.
15. Lin G., Wang JY., Li N. et al. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol. 2011; 54: 666-73.
16. Wang CC., Xia Q., Li M. et al. Metabolic activation of pyrrolizidine alkaloids leading to phototoxicity and photogenotoxicity in human HaCaT keratinocytes. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2014; 32: 362-84.
17. Crews C., Krska R. Pyrrolizidine alkaloids. In: Gilbert J., Senyuva HZ. (Ed.), Bioactive Compounds in Foods. Oxford, UK: Blackwell Publishing; 2008: 10-30.
18. Chen T., Mei N., Fu PP. Genotoxicity of pyrrolizidine alkaloids. J Appl Toxicol. 2010; 30: 183-96.
19. Roeder E. Medicinal plants in Europe containing pyrrolizidine alkaloids. Pharmazie. 1995; 50: 83-98.
20. Li N., Xia Q., Ruan J. et al. Hepatotoxicity and tumorigenicity induced by metabolic activation of pyrrolizidine alkaloids in herbs. Curr Drug Metab. 2011; 12: 823-34.
21. Fu PP., Xia Q., Lin G. et al. Pyrrolizidine alkaloids-genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev. 2004; 36: 1-55.
22. Mattocks AR. Chemistry and Toxicology of Pyrrolizidine Alkaloids. London: Academic Pr; 1986.
23. Dubecke A., Beckh G., Lullmann C. Pyrrolizidine alkaloids in honey and bee pollen. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2011; 28: 348-58.
24. Edgar JA., Colegate SM., Boppre M. et al. Pyrrolizidine alkaloids in food: a spectrum of potential health consequences. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2011; 28: 308-24.
25. Ma B., Li N., Lin G. Importance of metabolic activation study to the safe use of Chinese herbal medicines. Curr Drug Metab. 2012; 13: 652-58.
26. Helmy A. Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome. Aliment Pharmacol Ther. 2006; 23: 11-25.
27. DeLeve LD., Valla DC., Garcia-Tsao G. Vascular disorders of the liver. Hepatology. 2009; 49: 1729-64.
28. Mohabbat O., Younos MS., Merzad AA. et al. An outbreak of hepatic veno-occlusive disease in north-western Afghanistan. Lancet. 1976; 2: 269-71.
29. HB. Drought. Brings Back Gulran Disease. WHO Health Talks. Kabul, Afghanistan; 2001.
30. Dai N., Yu YC., Ren TH. et al. Gynura root induces hepatic veno-occlusive disease: a case report and review of the literature. World J Gastroenterol. 2007; 13: 1628-31.
31. Robinson O., Want E., Coen M. et al. Hirmi Valley liver disease: a disease associated with exposure to pyrrolizidine alkaloids and DDT. J Hepatol. 2014; 60: 96-102.
32. US Food. and Drug Administration. FDA Advises Dietary Supplement Manufacturers to Remove Comfrey Products from the Market. 2001. http://www.fda.gov/Food/RecallsOutbreaksEmergencies/SafetyAlertsAdvisories/ucm111219.htm.
33. UK Medicines. and Healthcare Products Regulatory Agency. Public consultation: Proposals to prohibit the sale, supply or importation of unlicensed medicinal products for internal use which contain Senecio species and proposals to amend three existing orders. 2007. http://www.mhra.gov.uk/Publications/Consultations/Medicinesconsultations/Othermedicinesconsultations/CON2030747.
34. Bundesgesundheitsamt (German Federal Health Bureau). Bekanntmachung ü ber die Zulassung und Registrierung von Arzneimitteln (Abwehr von Arzneimittelrisiken-Stufe II). Bundesanzeiger 1992; 33: 3.
35. Gao H., Li N., Wang JY. et al. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids. J Dig Dis. 2012; 13: 33-9.
36. Molyneux RJ., Gardner DL., Colegate SM. et al. Pyrrolizidine alkaloid toxicity in liverstock: a paradigm for human poisoning?. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2011; 28: 293-307.
37. Coulombe RA, Jr. Pyrrolizidine alkaloids in foods. Adv Food Nutr Res. 2003; 45: 61-99.
38. Ramachandran R., Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol. 2009; 62: 481-92.
39. Ruan J., Li N., Xia Q. et al. Characteristic ion clusters as determinants for the identification of pyrrolizidine alkaloid N-oxides in pyrrolizidine alkaloid-containing natural products using HPLC-MS analysis. J Mass Spectrom. 2012; 47: 331-7.
40. Lin G., Zhou KY., Zhao XG. et al. Determination of hepatotoxic pyrrolizidine alkaloids by on-line high performance liquid chromatography mass spectrometry with an electrospray interface. Rapid Commun Mass Spectrom. 1998; 12: 1445-56.
41. Health Department and National Chinese Medicine Management Office. Zhong Hua Ben Cao. Shanghai Science and Technology Publishing House; 1999.
42. Lin G., Li SL., Li M. et al. Qianliguang (Senecio scandens) safety dilemma: dose is the key?. Planta Med. 2009; 75: 1107-11.
43. Lin G., Rose P., Chatson KB. et al. Characterization of two structural forms of otonecine-type pyrrolizidine alkaloids from Ligularia hodgsonii by NMR spectroscopy. J Nat Prod. 2000; 63: 857-60.
44. Lin G., Nnane IP., Cheng TY. The effects of pretreatment with glycyrrhizin and glycyrrhetinic acid on the retrorsine-induced hepatotoxicity in rats. Toxicon. 1999; 37: 1259-70.
45. Ruan J., Yang M., Fu P. et al. Metabolic activation of pyrrolizidine alkaloids: insights into the structural and enzymatic basis. Chem Res Toxicol. 2014; 27: 1030-9.
46. Chen Z., Huo JR. Hepatic veno-occlusive disease associated with toxicity of pyrrolizidine alkaloids in herbal preparations. Neth J Med. 2010; 68: 252-60.
47. DeLeve LD., Shulman HM., McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis. 2002; 22: 27-42.
48. Elvidge T., Matthews IP., Gregory C. et al. Feasibility of using biomarkers in blood serum as markers of effect following exposure of the lungs to particulate matter air pollution. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2013; 31: 1-44.
49. Steven BY., Shawn K., Dwayne AH. et al. Synergistic hepatotoxicity from coexposure to bacterial endotoxin and the pyrrolizidine alkaloid monocrotaline. Toxicol Appl Pharm. 2000; 166: 173-85.
50. Katherine B. Microbiome: the bacterial tightrope. Nature. 2014; 516: S14-S6.